Search

Your search keyword '"Biotechnology -- Genetic aspects"' showing total 13 results
Start Over Descriptor "Biotechnology -- Genetic aspects" Publisher business wire, inc.
13 results on '"Biotechnology -- Genetic aspects"'

1. Puma Biotechnology's NERLYNX[R] Included in NCCN Clinical Practice Guidelines for the Treatment of Cervical Cancer with a HER2 Mutation

Subjects
National Comprehensive Cancer Network, Nerlynx (Medication), Drug therapy, Genetic aspects, Cancer treatment, Biotechnology -- Genetic aspects, Evidence-based medicine, Cervical cancer -- Genetic aspects -- Drug therapy, Cancer metastasis -- Genetic aspects -- Drug therapy, Neratinib, Metastasis -- Genetic aspects -- Drug therapy, Cancer -- Care and treatment
Abstract

LOS ANGELES -- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines([R])) for Cervical Cancer were [...]

Published
2024

2. iXCells Biotechnologies Expands CRISPR-Cas9 Cell Products and Genome Engineering Services

Subjects
Gene mutations -- Genetic aspects, Medical research, Medicine, Experimental, Genetic research -- Genetic aspects, Nervous system diseases -- Genetic aspects, Stem cells -- Genetic aspects, Biotechnology -- Genetic aspects, Drug discovery, Business, Business, international
Abstract

Gene Editing Services Deliver Disease Relevant Cell Models to Improve Preclinical Drug Development SAN DIEGO -- iXCells Biotechnologies ('iXCells' or the 'Company'), a provider of cell products and drug discovery [...]

Published
2023

3. Puma Biotechnology's NERLYNX[R] Included in NCCN Clinical Practice Guidelines for the Treatment of Breast Cancer with a HER2 Mutation

Subjects
Metastasis -- Genetic aspects -- Drug therapy, Biotechnology -- Genetic aspects, Cancer -- Care and treatment, Breast cancer -- Genetic aspects -- Drug therapy, Evidence-based medicine, Fulvestrant, Business, Business, international, National Comprehensive Cancer Network, Nerlynx (Medication)
Abstract

LOS ANGELES -- Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines([R])) for Breast Cancer were [...]

Published
2023

4. PerkinElmer's SIRION Biotech Teams with Centre for Genomic Regulation to Develop New Generation AAV Vectors for Type 1 and Type 2 Diabetes Gene Therapy

Subjects
PerkinElmer Inc., Medical research, Medicine, Experimental, Diabetes therapy, Genes -- Genetic aspects, Biotechnology -- Genetic aspects, Gene therapy, Vaccines, Genetic vectors -- Genetic aspects, Instrument industry, Type 2 diabetes -- Genetic aspects, Business, Business, international
Abstract

Collaboration aims to evolve precision medicine with cell-specific delivery of gene therapy WALTHAM, Mass. -- PerkinElmer, Inc.,a global leader committed to innovating for a healthier world, today announced that its [...]

Published
2022

6. Puma Biotechnology and Strata Oncology Announce Collaboration to Accelerate Enrollment in Neratinib HER2 Mutation Basket Study (SUMMIT Trial)

Subjects
Biotechnology -- Genetic aspects, Drug approval, Business, Business, international, Nerlynx (Medication) -- Product development
Abstract

LOS ANGELES & ANN ARBOR, Mich. -- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, and Strata Oncology, Inc., a precision oncology company, have entered into a collaborative agreement to [...]

Published
2018

7. Global Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) Pipeline Review 2016 Featuring Incyte, Inflection Biosciences, Jasco Pharma & Novartis - Research and Markets

Subjects
Biotechnology -- Genetic aspects, Protein kinases -- Genetic aspects, Business, Business, international
Abstract

DUBLIN -- Research and Markets has announced the addition of the 'Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) - Pipeline [...]

Published
2016

9. Celgene Corporation to Present at Deutsche Bank Securities Biotech Boston Confab Conference

Subjects
Deutsche Bank AG (Frankfurt, Germany), Celgene Corp., Banks (Finance) -- Genetic aspects, Biotechnology -- Genetic aspects, Banking industry -- Genetic aspects, Pharmaceutical industry -- Genetic aspects, Banking industry, Business, Business, international
Abstract

SUMMIT, N.J. -- Celgene Corporation (NASDAQ:CELG) today announced its presentation at the Deutsche Bank Securities Biotech Boston Confab Conference on Tuesday, December 15, 2009 at 11:00 a.m. ET will be [...]

Published
2009

10. Celgene Corporation to Present at the 3rd Annual Citi Biotech Day

Subjects
Celgene Corp., Pharmaceutical industry -- Genetic aspects, Biotechnology -- Genetic aspects, Business, Business, international
Abstract

SUMMIT, N.J. -- Celgene Corporation (NASDAQ: CELG) today announced its presentation at the 3rd Annual Citi Biotech Day on Monday, September 8, 2008 at 9:00 a.m. EDT will be webcast [...]

Published
2008

11. Celgene Corporation to Present at the NewsMakers in the Biotech Industry Conference

Subjects
Celgene Corp., Pharmaceutical industry -- Genetic aspects, Biotechnology -- Genetic aspects, Biotechnology industry -- Genetic aspects, Business, Business, international
Abstract

SUMMIT, N.J. -- Celgene Corporation (NASDAQ: CELG) today announced its presentation at the NewsMakers in the Biotech Industry Conference on Thursday, September 4, 2008 at 2:00 p.m. EDT will be [...]

Published
2008

12. Celgene Corporation to Present at Citibank Biotech Day

Subjects
Citibank N.A. (New York, New York), Celgene Corp., Biotechnology -- Genetic aspects, Banking industry -- Genetic aspects, Pharmaceutical industry -- Genetic aspects, Banking industry, Business, Business, international
Abstract

SUMMIT, N.J. -- Celgene Corporation (NASDAQ: CELG) announced today that its presentation at the Citibank Biotech Day on Monday, November 12, 2007 at 11:30 am EST will be webcast live [...]

Published
2007

13. Celgene Corporation to Present at the NewsMakers in the Biotech Industry Conference

Subjects
Celgene Corp., Pharmaceutical industry -- Genetic aspects, Biotechnology -- Genetic aspects, Biotechnology industry -- Genetic aspects, Business, Business, international
Abstract

SUMMIT, N.J. -- Celgene Corporation (NASDAQ: CELG) announced today that its presentation at the NewsMakers in the Biotech Industry Conference on Thursday, September 6, 2007 at 3:00 pm EDT will [...]

Published
2007

Catalog

Books, media, physical & digital resources
See catalog results